Takeda Pharmaceutical Company Ltd
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
Completed
- Conditions
- Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 560
- Registration Number
- NCT03219723
- Locations
- π―π΅
Takeda Selected Site, Tokyo, Japan
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 272
- Registration Number
- NCT03215030
- Locations
- πΊπΈ
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
πΊπΈBoston Medical Center, Boston, Massachusetts, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"
Completed
- Conditions
- Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3183
- Registration Number
- NCT03214952
- Locations
- π―π΅
Takeda Selected Site, Tokyo, Japan
Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1304
- Registration Number
- NCT03214198
- Locations
- π―π΅
Takeda Selected Site, Tokyo, Japan
Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use"
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1119
- Registration Number
- NCT03214094
- Locations
- π―π΅
Takeda Selected Site, Tokyo, Japan
Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1237
- Registration Number
- NCT03214081
- Locations
- π―π΅
Takeda Selected Site, Tokyo, Japan
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 333
- Registration Number
- NCT03209492
- Locations
- π―π΅
Takeda Selected Site, Tokyo, Japan
Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 312
- Registration Number
- NCT03209518
- Locations
- π―π΅
Takeda selected site, Tokyo, Japan
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Phase 2
Active, not recruiting
- Conditions
- Crohn's DiseaseUlcerative Colitis
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 59
- Registration Number
- NCT03196427
- Locations
- πΊπΈ
Seattle Children's Hospital, Seattle, Washington, United States
πΊπΈCedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈChildren's Center for Digestive Healthcare, Atlanta, Georgia, United States
Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Other: No Intervention
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 282
- Registration Number
- NCT03188536
- Locations
- πͺπΈ
H Marques de Valdecilla, Santander, Cantabria, Spain
πͺπΈH Universitario de Cabuenes, Gijon, Asturias, Spain
πͺπΈH Universitario Puerta del Mar, Cadiz, Andalucia, Spain
Β© Copyright 2025. All Rights Reserved by MedPath